Blood advances
Ropeginterferon alfa-2b has minimal transplacental passage and breastmilk secretion in pregnant MPN patients.
Tsewang Tashi, Lee-Yung Shih, Yi-Te Yo, Amy Sullivan, Ho-Yen Chueh, Ming-Chung Kuo, Amanda Smith, Soo Jin Kim, Brynn Parsegov, Brandi N Reeves, Jihyun Song, Josef T Prchal
Published: 202610.1182/bloodadvances.2025018811
Abstract
Pregnancy in patients with myeloproliferative neoplasms (MPNs) poses unique challenges due to increased risks of maternal complications and adverse fetal outcomes. Interferon-alpha (IFN-α) has been shown to be safe and is the preferred cytoreductive…
Preview only. Read the full abstract at the source